149 related articles for article (PubMed ID: 38304429)
21. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis.
Cao YZ; Zheng GL; Zhang TQ; Shao HY; Pan JY; Huang ZL; Zuo MX
World J Gastroenterol; 2024 Jan; 30(4):318-331. PubMed ID: 38313229
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Baseline
Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
[TBL] [Abstract][Full Text] [Related]
23. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.
Tian BW; Yan LJ; Ding ZN; Liu H; Han CL; Meng GX; Xue JS; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
Int Immunopharmacol; 2023 Jan; 114():109519. PubMed ID: 36459922
[TBL] [Abstract][Full Text] [Related]
24. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
25. New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.
Lin X; Chen X; Long X; Zeng C; Zhang Z; Fang W; Xu P
Respir Res; 2023 Feb; 24(1):64. PubMed ID: 36849947
[TBL] [Abstract][Full Text] [Related]
26. Novel Prognostic Nomograms for Hepatocellular Carcinoma Patients with Microvascular Invasion: Experience from a Single Center.
Xu L; Li L; Wang P; Zhang M; Zhang Y; Hao X; Yan L; Li B; Wen T; Xu M
Gut Liver; 2019 Nov; 13(6):669-682. PubMed ID: 30970430
[TBL] [Abstract][Full Text] [Related]
27. Factors affecting overall survival and disease-free survival after surgery for hepatocellular carcinoma: a nomogram-based prognostic model-a Western European multicenter study.
Masuda Y; Yeo MHX; Burdio F; Sanchez-Velazquez P; Perez-Xaus M; Pelegrina A; Koh YX; Di Martino M; Goh BKP; Tan EK; Teo JY; Romano F; Famularo S; Ferrari C; Griseri G; Piardi T; Sommacale D; Gianotti L; Molfino S; Baiocchi G; Ielpo B
Updates Surg; 2024 Jan; 76(1):57-69. PubMed ID: 37839048
[TBL] [Abstract][Full Text] [Related]
28. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
[TBL] [Abstract][Full Text] [Related]
29. Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score.
Li Y; Pan Y; Lin X; Hou J; Hu Z; Xu L; Zhou Z; Zhang Y; Chen M; Hu D
Front Pharmacol; 2021; 12():819985. PubMed ID: 35237150
[No Abstract] [Full Text] [Related]
30. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
31. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
32. C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients.
Kankkunen E; Penttilä P; Peltola K; Bono P
Acta Oncol; 2022 Oct; 61(10):1240-1247. PubMed ID: 35905053
[TBL] [Abstract][Full Text] [Related]
33. Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma.
Liu H; Gan XM; Sun JM; Yang Q; Zhang DZ; Zuo YQ; Liu FL; Li B; Tan QL; Zhang J
Int Immunopharmacol; 2024 Mar; 130():111510. PubMed ID: 38422766
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors.
Liu C; Zhao H; Zhang R; Guo Z; Wang P; Qu Z
Oncol Lett; 2023 Oct; 26(4):437. PubMed ID: 37664652
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of postoperative change of PALBI grade for patients with hepatocellular carcinoma after hepatectomy.
Wang ZX; Peng W; Zhang XY; Wen TF; Li C
Medicine (Baltimore); 2021 Mar; 100(11):e24476. PubMed ID: 33725934
[TBL] [Abstract][Full Text] [Related]
36. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
[No Abstract] [Full Text] [Related]
37. Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy.
Guo DZ; Zhang SY; Dong SY; Yan JY; Wang YP; Cao Y; Rao SX; Fan J; Yang XR; Huang A; Zhou J
Front Immunol; 2023; 14():1141199. PubMed ID: 36911686
[TBL] [Abstract][Full Text] [Related]
38. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M
J Hepatol; 2022 Feb; 76(2):353-363. PubMed ID: 34648895
[TBL] [Abstract][Full Text] [Related]
39. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
Lee PC; Wu CJ; Hung YW; Lee CJ; Chi CT; Lee IC; Yu-Lun K; Chou SH; Luo JC; Hou MC; Huang YH
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738801
[TBL] [Abstract][Full Text] [Related]
40. Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response.
Yang F; Xu GL; Huang JT; Yin Y; Xiang W; Zhong BY; Li WC; Shen J; Zhang S; Yang J; Sun HP; Wang WS; Zhu XL
Front Immunol; 2022; 13():847601. PubMed ID: 35300339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
